Liraglutide — NZ Medication Guide
✅ Reviewed by Ramon Wong, BPharm, Registered Pharmacist (New Zealand) | May 2026
This information is for educational purposes only and is not a substitute for personalised advice from your doctor or pharmacist. Always seek professional guidance before making changes to your medications.
What is Liraglutide?
📬 Get weekly Pharmac updates and medication news — join the free KiwiMeds Bulletin at kiwimeds.nz/newsletter
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes and obesity management. This medication is funded by Pharmac under Special Authority for type 2 diabetes with CVD; Saxenda® not funded for obesity.
What is Liraglutide Used For?
Liraglutide (Victoza®) is used for type 2 diabetes to improve glycaemic control, reduce cardiovascular risk, and promote modest weight loss. At a higher dose (Saxenda® 3 mg/day), it is also approved for chronic weight management in adults with obesity.
How Does Liraglutide Work?
Liraglutide is an analogue of GLP-1, a gut hormone that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic receptors. This lowers post-meal glucose, promotes satiety, and reduces caloric intake.
How to Take Liraglutide
Self-administered by subcutaneous injection once daily (any time of day, with or without food). For Victoza®: start at 0.6 mg/day for 1 week, increase to 1.2 mg/day, then 1.8 mg/day. For Saxenda® (weight management): titrate from 0.6 mg/day up to 3 mg/day over 5 weeks.
Common Side Effects of Liraglutide
- Nausea and vomiting (very common — usually improves over 4–8 weeks)
- Diarrhoea or constipation
- Injection site reactions (redness, bruising, nodules)
- Headache
- Reduced appetite
Serious Side Effects — Seek Medical Attention
Contact your doctor or call 111 immediately if you experience any of the following:
- Pancreatitis (rare — stop and seek medical care if persistent severe abdominal pain)
- Thyroid tumours (C-cell tumours seen in rodents — avoid in patients with personal or family history of medullary thyroid carcinoma or MEN2)
- Diabetic retinopathy worsening (with rapid glucose reduction)
- Severe dehydration (from vomiting/diarrhoea)
- Renal impairment (secondary to dehydration)
Drug Interactions
Liraglutide may interact with other medicines. Always inform your doctor and pharmacist of all medications you are taking. Key interactions include:
- Insulin and sulfonylureas (hypoglycaemia risk — consider dose reduction)
- Oral medicines with narrow therapeutic windows (liraglutide slows gastric emptying — affects absorption timing)
- Warfarin (monitor INR)
New Zealand Prescribing Information
Liraglutide (Victoza® 6 mg/mL pre-filled pen) is funded by Pharmac under Special Authority for type 2 diabetes with established cardiovascular disease, as add-on to metformin. Saxenda® (higher-dose liraglutide 3 mg) for weight management is not funded in NZ and requires private purchase. Cardiovascular outcome data from the LEADER trial support liraglutide’s use in high-risk diabetic patients.
Frequently Asked Questions
How do I manage nausea on liraglutide?
Start with the lowest dose (0.6 mg) and increase slowly over weeks. Eat smaller, lower-fat meals. Nausea typically improves significantly within 4–8 weeks. If vomiting is severe, contact your doctor.
Is liraglutide just for diabetes?
At the standard dose (up to 1.8 mg/day), liraglutide is used for type 2 diabetes. At the higher dose of 3 mg/day (Saxenda®), it is approved for weight management in people with obesity. In NZ, Saxenda® is not funded and requires private prescription.
⚠️ Disclaimer: This page is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or a qualified health provider. In New Zealand, medication availability and funding may vary — check with Pharmac or your pharmacist for current information.
Reviewed by a Registered Pharmacist NZ
References & Further Information
The following New Zealand and international resources were used to inform this page: